STAT
Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval
Day One Biopharmaceuticals said Sunday that a targeted therapy shrank tumors by at least 50% in a majority of children with the most common form of pediatric brain cancer, setting up a potential approval in a rare disease long overlooked by drugmakers. The new data expand on earlier results released last year from 22 patients.
More